Stocks · News reference
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, announced the filing
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $29.
Read original at benzingaBTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $34 price target.
Read original at benzinga